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Case Report
Risperidone-Induced Psychosis and Depression in a
Child with a Mitochondrial Disorder
Mary S. Ahn, M.D.,1,2,3 Katherine B. Sims, M.D.,4,5 and Jean A. Frazier, M.D.1,3,6
ABSTRACT
Objective: To our knowledge, this is the first published case report of an adolescent girl with
a mitochondrial disorder and depression who displayed both new-onset psychotic and in-
creased mood symptoms during treatment with risperidone.
Data: A 16-year-old girl was treated with risperidone for mood lability and impulsivity at a
community hospital. Within days, she developed paranoid ideation, profound psychomotor
retardation, increased depression, and fatigue. She was transferred to an inpatient psychi-
atric hospital, where she was taken off risperidone. Within 48 hours after discontinuation of
the medication, she had complete resolution of psychotic symptoms, fatigue, and psychomo-
tor retardation, and her depression improved.
Conclusions: This observation of “on-off” risperidone treatment suggests that risperidone
may have worsened both psychiatric and physical manifestations of the mitochondrial disor-
der in this adolescent. These findings are consistent with recent in vitro literature, which im-
plicate a series of neuroleptic medications with mitochondrial dysfunction.  Furthermore, the
authors provide diagnostic and treatment options that are available for mitochondrial disor-
ders, which are of interest to child psychiatrists due to the central nervous system manifesta-
tions of these disorders.
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INTRODUCTION
MITOCHONDRIAL DISORDERS were first describedby Rolf Luft in 1962 (Luft et al. 1962) and
refer to dysfunction of energy metabolism by
different pathways including: (1) oxidative
phosphorylation, (2) fatty acid oxidation, and/
or (3) Krebs Cycle. Oxidative phosphorylation
creates adenosyl triphosphate (ATP), which is
essential for energy metabolism and vital for
the normal function of bodily organs. There-
fore, mitochondrial disorders may lead to clin-
ical manifestations involving almost any organ
system (Zeviani and Di Donato 2004). The most
common clinical presentations in a recent ret-
rospective review of 113 children with mito-
chondrial disease include cardiomyopathy (40%)
and nonspecific encephalopathy (39%). The chil-
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dren without cardiomyopathy were further
studied and 100% had developmental delays,
79% had hypotonia, 20% had hypertonia, 50%
had seizures, 12% had movement disorders,
6% had ataxia, 21% had sensorineural hearing
loss, and 32% had ophthalmologic abnormali-
ties (Scaglia et al. 2004). (Please refer to Table 1,
which lists the most common presentations of
mitochondrial disorders.) Mitochondrial disor-
ders have been also implicated in neurodegen-
erative disorders, as neurons are susceptible to
oxidative damage. By extension, one would
expect that neuropsychiatric manifestations
would occur secondary to mitochondrial dis-
orders, though this remains an understudied
area. A recent study estimates the prevalence
of mitochondrial disorders to be 1 of 5000
births, although the authors argue that this is
a conservative estimate, given their heteroge-
neous genotypic and phenotypic presentations
(Thorburn 2004).
Typical and atypical neuroleptics are com-
monly prescribed for a variety of childhood
psychiatric conditions, including psychotic dis-
orders, mood disorders, and disruptive behav-
ior disorders (Armenteros et al. 1997; Grcevich
et al. 1996; Frazier et al. 1999; McDougle et al.
1997; Snyder et al. 2002; Horrigan and Barnhill
1997; Schreier 1998; Buitelaar 2000; Buitelaar et
al. 2001; Gaffney et al. 2002). They have also
been used to treat emotional and behavioral dys-
regulation in youth with underlying mitochon-
drial disorders. However, in vitro data using rat
liver have shown that both typical and atypi-
cal neuroleptics inhibit mitochondrial oxidative
phosphorylation (Modica-Napolitano et al. 2003).
Also, in vitro neuroleptic medications (haloperi-
dol, chlorpromazine, and thiothixene) have been
shown to inhibit electron transport chain com-
plex I enzyme activity in rat brain mitochon-
dria (Burkhardt et al. 1993) and human brain
(haloperidol, chlorpromazine, risperidone and,
to a much lesser extent, clozapine) (Maurer and
Moller 1997). As such, neuroleptics might be
expected to exacerbate the very neuropsychiatric
symptoms that they are being used to treat in
people with already compromised dysfunction
of energy metabolism owing to a mitochondr-
ial disorder.
We present the following case of a young
woman with a mitochondrial disorder whose
subsequent clinical course may illustrate the
complications that can arise from treatment
with an atypical neuroleptic in individuals with
these disorders. We also use the case as a way
to discuss the recognition and management of
a mitochondrial disorder within a neuropsy-
chiatric context.
CASE REPORT
A 16-year-old girl, JM, with a low-average
IQ, speech and motor delays, and a significant
medical history of a mitochondrial and seizure
disorder, was brought in by her mother to a
community hospital’s psychiatric emergency
program for parasuicidal behavior.
History of mitochondrial disorder
JM’s mitochondrial disorder first came to light
as part of an evaluation for seizures. She expe-
rienced tonic-clonic seizures at 5 years of age,
with seizures occurring three to four times per
week. JM underwent a thorough neurological
workup, including magnetic resonance imaging
(MRI), which was within normal limits. During
her seizures, JM experienced profound muscle
weakness that made the neurologist suspicious
of an underlying mitochondrial disorder. Her
lactate level (one of the tests for diagnosing
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TABLE 1. COMMON PRESENTATIONS CONSISTENT WITH MITOCHONDRIAL DISORDERS
(MUNNICH ET AL. 1996; DIMAURO ET AL. 2004)
Central nervous system seizures, myoclonus, ataxia, psychiatric symptoms, cognitive decline, headaches
Cardiac cardiomyopathy, heart block
Endocrine diabetes, growth-hormone deficiency/short stature, hypothyroidism, hypoparathyroidism
Muscle muscle weakness
Optic ptosis, visual changes
Otic deafness
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mitochondrial disorders) was elevated, and,
therefore, a muscle biopsy was performed. The
presence of ragged red fibers confirmed the di-
agnosis of a mitochondrial disorder. Clinically,
JM improved on a cocktail for mitochondrial
disorders, consisting of carnitine supplementa-
tion (Carnitor) and Coenzyme Q-10 supple-
mentation. Her seizures dramatically decreased
to once or twice annually. 
Psychiatric history
When JM was brought to the emergency
room, she had been depressed, cutting herself
superficially on the arms and taking extra ibu-
profen and extra seizure medication to relieve
psychic pain. The self-mutilation began after
learning that a close relative was diagnosed
with cancer, and that her brother had been sex-
ually molested. In addition to cutting herself,
JM had sleep disturbance, poor appetite, and
decreased interests. There was no history of
psychomotor retardation, increased fatigue or
guilt, decreased concentration, or manic or psy-
chotic symptoms. JM began contemplating sui-
cide but never thought of a plan. She took
excessive amounts of ibuprofen and levetirac-
etam (Keppra) the night before her presentation
as a way to “numb the pain,” rather than as a
suicide attempt. Prior to the recent stressors, she
and the family denied any psychiatric problems.
Family history
An uncle had a history of posttraumatic stress
disorder and depression after the Vietnam War.
There was no other psychiatric family history.
The medical family history was positive for
seizure disorders and asthma. There was no
family history of developmental delay or mito-
chondrial disorders.
Treatment history
JM’s medications included: Levetiracetam
(Keppra) 1000 mg twice-daily prescribed for
her seizure disorder; carnitine (Carnitor) 700
mg three times a day; multivitamin daily; and
Coenzyme Q-10 200 mg twice-daily. The carni-
tine, multivitamin, and Co-Q were taken for her
underlying mitochondrial disorder, and there
were no changes in this medication regimen
for over 1 year. Her primary care physician had
prescribed paroxetine 1 week prior to her pre-
sentation to the community hospital owing to
concerns of depression, but she had not filled
the prescription.
Hospital course
Because of the unavailability of inpatient psy-
chiatric beds in the area, JM boarded on the pe-
diatric service of a community hospital for 4
days awaiting transfer. On the first hospital day,
a psychiatric consultant recommended starting
the paroxetine 10 mg daily for her depression
and risperidone 0.5 mg twice-daily to address
impulsivity. Admission laboratory data showed
a negative urine toxicology screen. Her com-
plete blood count, electrolytes, liver profile, vital
signs, and electrocardiogram were all within
normal limits. Her urine pregnancy test was neg-
ative. No lactate or pyruvate levels were drawn.
On hospital day 5, JM was transferred to the
in-patient child psychiatric unit and received
an evaluation by the first author. At this time,
JM’s mental status examination was notable
for a clear change from the report of her men-
tal status prior to starting risperidone. She pre-
sented as irritable, guarded, and with severe
psychomotor retardation. She denied halluci-
nations but appeared to be attending to inter-
nal stimuli. She displayed paranoid ideation
towards her family and staff members. JM
complained of fatigue and of an acute deficit
in concentration. There was worsening of her
depressed mood. Her admission Abnormal In-
voluntary Movement Scale (AIMS) examina-
tion was zero.
Later that day, JM was taken off risperidone
because of questionable clinical indication and
concerns about its effects on her underlying
mitochondrial disorder, as the examiner was
familiar with the recent literature about neu-
roleptics and mitochondrial dysfunction. JM
continued on the same doses of her other med-
ications, including the paroxetine.
Within 48 hours after stopping the risperi-
done, JM showed complete resolution of her
paranoid ideation, was no longer attending to
internal stimuli, and was no longer feeling fa-
tigued. Her concentration improved. She still
522 AHN ET AL.
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complained of urges to cut herself and re-
ceived skills therapy on the unit to address
these maladaptive behaviors. Her mother, who
had noticed a dramatic deterioration in her
daughter’s mental status while on risperidone
and paroxetine, also noted the improvement
once the risperidone was stopped.
JM was discharged home in stable condition
after 13 inpatient psychiatric hospital days.
DISCUSSION
In this case report, we present an adolescent
girl with a history of developmental delays,
and a mitochondrial disorder who, prior to acute
stressors, had no psychiatric history. She re-
sponded to her acute stressors with depression
and maladaptive coping skills. There was no
history of psychosis prior to taking the psy-
chotropic medications. She was started on
risperidone, and within 48 hours of initiating
the medication she experienced paranoid idea-
tion, profound psychomotor retardation, and
worsening of her depression. There was no in-
dication of extrapyramidal symptoms (EPS)
secondary to risperidone. These symptoms of
psychosis resolved after the risperidone was
discontinued.
Lactate and pyruvate levels, as well as amino
acid and organic acid levels, might have con-
firmed the relationship of JM’s clinical status
to risperidone, but were not obtained during
this “on-and-off” evaluation. There are, of course,
other possible reasons for worsening of her
clinical status. These include: (1) a drug-drug
interaction in this patient between risperidone
and paroxetine; (2) an idisosyncratic reaction
to risperidone unrelated to worsening of mito-
chondrial functioning; (3) a progression of the
patient’s underlying depression; and/or (4) a
neuropsychiatric progression of the patient’s
underlying mitochondrial disorder unrelated
to the medication treatment. However, given
JM’s rapid resolution of psychiatric symptoms
after the risperidone was discontinued, the
most likely reason for the symptom exacerba-
tion involved exposure to risperidone, whether
it represented a drug-drug interaction with
paroxetine, an unrelated idiosyncratic reaction
to risperidone, or a direct effect of the risperi-
done on mitochondrial function. Given JM’s
history of mitochondrial dysfunction and the
data suggesting that neuroleptics can worsen
mitochondrial function, it is not unreasonable
to conclude that her deterioration was related
to risperidone’s effect on mitochondrial oxida-
tive phosphorylation.
There have been published case reports of
increased psychiatric and physical difficulties
in adults with mitochondrial disorders who
were treated with neuroleptics (Kaido et al. 1996;
Yamazaki et al. 1991; Spellberg et al. 2001;
Iizuka et al. 2003). For example, Yamazaki et
al. report a 37-year-old male with an 8-year
history of psychosis and dementia, who later
developed hyperpyrexia and dystonia after
haloperidol administration. Both his dystonia
and psychiatric symptoms resolved after being
diagnosed with a mitochondrial disorder named
MELAS (mitochondrial encephalopathy, lactic
acidosis, and stroke-like syndrome) and being
placed on Coenzyme Q-10 and taken off halo-
peridol (1996). Of note, MELAS has been de-
scribed together with psychiatric symptoms
even before stroke-like episodes have taken
place (Suzuki et al. 1990). These findings raise
the question whether mitochondrial dysfunction
increases vulnerability to psychiatric symptoms
in certain primary mitochondrial disorders.
Clinical implications
This case report brings up several issues in
the clinical treatment of children with psychi-
atric symptoms. Firstly, children with psychosis
are often evaluated for organic pathology as a
part of routine clinical practice, but mitochon-
drial disorders screening is not commonly part
of that organic work-up. Although mitochon-
drial disorders are relatively rare, clinicians
should be mindful that evidence of: (1) devel-
opmental delays; and/or (2) multiple comorbid
medical problems (i.e., other organ or multior-
gan dysfunction); and/or (3) chronic, intermit-
tent, or progressive medical and psychiatric
disorders with episodes of exacerbation; and/
or (4) positive family history (both maternal
and Mendelian inheritance) for mitochondrial
diseases or multiorgan pathology without an
identifiable etiology, should raise the suspicion
that new-onset psychiatric symptoms may be
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the result of an underlying mitochondrial dis-
order. If a mitochondrial disorder is present or
even suspected, the risks of worsening the un-
derlying mitochondrial dysfunction should be
weighed against the benefits of neuroleptic med-
ications. If clinically necessary, neuroleptics
with the least risk of EPS should be considered
first, as the degree of mitochondrial dysfunction
associated with neuroleptic treatment is asso-
ciated with extrapyramidal symptom (EPS) risk.
Furthermore, children with mitochondrial dis-
orders need to be carefully evaluated for EPS,
tardive dyskinesia, psychosis, and worsening
of neuropsychiatric symptoms and progression
of physical symptoms associated with their un-
derlying mitochondrial disease.
With respect to evaluation, there is no pathog-
nomonic test for mitochondrial disorders. Al-
though adult diagnostic criteria have been
proposed, childhood diagnostic criteria are not
yet formalized (Bernier et al. 2002; Skladal et
al. 2003; Scaglia et al. 2004). However, impor-
tant initial screening tests for mitochondrial
disorders include: (1) serum lactate and pyru-
vate levels, although only 60% of cases with
mitochondrial disorder exhibit elevated levels
of lactate and serum pyruvate; (2) a nonfasting
urinalysis positive for ketones; and (3) serum
ammonia, fasting glucose, serum for quantita-
tive amino acids, and urine for quantitative or-
ganic acids (Munnich et al. 1996; Spellberg et
al. 2001; Bernier et al. 2002; Prietsch et al. 2002;
Smeitink 2003; Hunter et al. 2004; DiMauro et
al. 2004).
In cases with a compelling clinical history
and/or positive screening tests consistent with
mitochondrial disorder, neurological consulta-
tion should be sought to pursue additional
studies. The neurologist may recommend mus-
cle biopsy in order to examine for the presence
of histological abnormalities (including ragged
red fibers), or histochemical changes by light
microscopy and anatomic mitochondrial find-
ings (crystalline inclusions, subsarcolemmal
clustering) in skeletal muscle. Histological skele-
tal muscle abnormalities can support a diagno-
sis of a mitochondrial disorder, but are not
sensitive, as 17% of patients had normal find-
ings in Scaglia et al. (2004). Direct assay of elec-
tron chain complexes may highlight specific
deficiency. Other diagnostic tests include genetic
testing (nDNA or mtDNA), or organ-specific
provocative testing.
There is no singular cure for mitochondrial
disorders, and treatment is based on support-
ively managing symptoms. Supplementation
with enzyme cofactors (Coenzyme Q-10, Vita-
min K, B Vitamins), important mitochondrial
transport factors (carnitine), dietary changes,
and a “vitamin cocktail” rich in antioxidants
may be warranted. Medications, which are
known to inhibit oxidative phosphorylation,
should be avoided if possible, including val-
proic acid, barbiturates, tetracylines, chloram-
phenicol, and certain neuroleptics (Munnich et
al. 1996; Modica-Napolitano et al. 2003). If neu-
roleptics are clinically necessary, olanzapine
(Zyprexa) and clozapine (Clozaril) should be
considered, followed by quetiapine (Seroquel),
owing to the fact that these agents show the
least amount of mitochondrial dysfunction in
animal studies (Modica-Napolitano et al. 2003).
CONCLUSIONS
Taken together, these findings lend further
support for the need to systematically investi-
gate psychiatric phenotypic expression of mi-
tochondrial disorder and highlight the need to
systematically evaluate the safety and efficacy
of neuroleptic treatment in youths who suffer
from these disorders.
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